DRC Launches Tumaini Trial for Bundibugyo Virus Vaccine
The Democratic Republic of the Congo (DRC) has launched a Phase 2/3 clinical trial to evaluate vaccine candidates against the Bundibugyo virus, following the vaccination of the first participant in Bunia. This event marks the beginning of the Tumaini trial, which is part of the DRC's response to the ongoing outbreak.
Jodie Rogers, Senior Communications and Advocacy Manager at the Coalition for Epidemic Preparedness Innovations (CEPI), stated that the trial aims to assess the safety, immune response, and effectiveness of potential vaccines, as there is currently no approved vaccine for human use against this virus. The outbreak, declared on May 15, has resulted in 9,552 cases and 4,602 deaths as of October 21.
The trial will evaluate multiple vaccine candidates, including Ervebo, which is licensed for Ebola but whose effectiveness against Bundibugyo remains unknown. The study will utilize an adaptive platform design and a ring vaccination strategy, focusing on individuals at higher risk of infection.
Plus234Feed summary based on reporting from The Will. Read the original report below.
Read full article
Continue on The Will
Get the week in one email
Top stories, NPFL results, the naira, every Friday morning. Free, one email a week.
Related Stories
DR Congo Launches Ebola Prevention Drug Trial
WHO Allocates 20,000 Ervebo Doses for Ebola Trial
Congo Launches Ebola Vaccination for Health Workers
CEPI Allocates $3.9M for Ebola Vaccine Research in DRC
WHO Reports Worsening Ebola Outbreak in DR Congo
Nigeria Reports First Ebola Case from Bundibugyo Strain
Get Plus234Feed on messaging apps
Same headlines, delivered where you already scroll.
